InvestorsHub Logo
Post# of 251121
Next 10
Followers 827
Posts 119251
Boards Moderated 16
Alias Born 09/05/2002

Re: None

Friday, 03/02/2018 10:52:25 AM

Friday, March 02, 2018 10:52:25 AM

Post# of 251121
(GILD)—MYL launches two HIV FDCs in US market:

https://www.prnewswire.com/news-releases/mylan-to-introduce-two-new-cost-saving-hiv-combination-treatments-in-the-us-300607274.html

MYL’s Symfi Lo is a 3-DAA FDC positioned as replacement for GILD’a Atripla; it contains the constituents in Atripla except that Lamivudine has been substituted for Emtriva (which is still on-patent in the US).

MYL’s Cimduo is a 2-DAA FDC positioned as a replacement for GILD’s Truvada, where (as above) Lamivudine has been substituted for Emtriva.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.